CN112703206A - 靶向肿瘤的重组双功能融合蛋白及其应用 - Google Patents
靶向肿瘤的重组双功能融合蛋白及其应用 Download PDFInfo
- Publication number
- CN112703206A CN112703206A CN202080002411.8A CN202080002411A CN112703206A CN 112703206 A CN112703206 A CN 112703206A CN 202080002411 A CN202080002411 A CN 202080002411A CN 112703206 A CN112703206 A CN 112703206A
- Authority
- CN
- China
- Prior art keywords
- tumor
- antibody
- tgf
- fusion protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 209
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 131
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 131
- 230000018883 protein targeting Effects 0.000 title abstract description 4
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims abstract description 102
- 102100022464 5'-nucleotidase Human genes 0.000 claims abstract description 89
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 59
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 41
- 230000027455 binding Effects 0.000 claims abstract description 40
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 20
- 210000002865 immune cell Anatomy 0.000 claims abstract description 20
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims abstract description 11
- 230000008685 targeting Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 83
- 210000004881 tumor cell Anatomy 0.000 claims description 42
- 150000001413 amino acids Chemical group 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 31
- 241000282414 Homo sapiens Species 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 206010059866 Drug resistance Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 230000004614 tumor growth Effects 0.000 claims description 15
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 14
- 241001529936 Murinae Species 0.000 claims description 14
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 11
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 11
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 11
- 229960005305 adenosine Drugs 0.000 claims description 11
- 230000004761 fibrosis Effects 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000001976 enzyme digestion Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 7
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000012292 cell migration Effects 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 9
- 108010000499 Thromboplastin Proteins 0.000 description 51
- 102100030859 Tissue factor Human genes 0.000 description 51
- 210000002540 macrophage Anatomy 0.000 description 40
- 230000008595 infiltration Effects 0.000 description 31
- 238000001764 infiltration Methods 0.000 description 31
- 238000010166 immunofluorescence Methods 0.000 description 22
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000002055 immunohistochemical effect Effects 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 13
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 102000045309 human NT5E Human genes 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 9
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012286 ELISA Assay Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 102000004008 5'-Nucleotidase Human genes 0.000 description 5
- 108700004024 5'-Nucleotidase Proteins 0.000 description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 210000005008 immunosuppressive cell Anatomy 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012137 double-staining Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101710132701 Protein L1 Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000011398 antitumor immunotherapy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000010406 dendritic cell apoptotic process Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- -1 succinimidyl ester Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
一种靶向肿瘤的重组双功能融合蛋白及其应用,具体提供了一种重组双功能融合蛋白,其包含特异性结合靶分子CD73或TF蛋白的第一结合结构域和特异性结合靶分子TGFβ蛋白的第二结合结构域;以及所述抗体融合蛋白的制备方法及其应用。CD73/TF‑TGFβR融合蛋白通过高特异性地阻抑肿瘤微环境中的CD73‑TGFβ或TF‑TGFβ表达水平,改善肿瘤免疫细胞环境,增强肿瘤治疗的效果。该融合蛋白具有很高的靶向亲和力及显著的抗肿瘤活性。
Description
PCT国内申请,说明书已公开。
Claims (24)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910838651.0A CN112442132A (zh) | 2019-09-05 | 2019-09-05 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
CN2019108386510 | 2019-09-05 | ||
PCT/CN2020/113357 WO2021043229A1 (zh) | 2019-09-05 | 2020-09-04 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112703206A true CN112703206A (zh) | 2021-04-23 |
CN112703206B CN112703206B (zh) | 2023-12-05 |
Family
ID=74733242
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910838651.0A Pending CN112442132A (zh) | 2019-09-05 | 2019-09-05 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
CN202080002411.8A Active CN112703206B (zh) | 2019-09-05 | 2020-09-04 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910838651.0A Pending CN112442132A (zh) | 2019-09-05 | 2019-09-05 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN112442132A (zh) |
WO (1) | WO2021043229A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113450877A (zh) * | 2021-06-28 | 2021-09-28 | 深圳裕泰抗原科技有限公司 | 一种基于多重免疫组化技术的生物标志物分析方法及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113773401B (zh) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和pd-l1的重组融合蛋白及其制备和用途 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
KR20240000394A (ko) * | 2022-06-22 | 2024-01-02 | (주)지아이이노베이션 | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104788567A (zh) * | 2015-01-21 | 2015-07-22 | 武汉友芝友生物制药有限公司 | 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用 |
CN106103488A (zh) * | 2014-02-10 | 2016-11-09 | 默克专利有限公司 | 靶向TGFβ抑制 |
CN106467574A (zh) * | 2015-08-20 | 2017-03-01 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
CN107001474A (zh) * | 2014-11-21 | 2017-08-01 | 百时美施贵宝公司 | 抗cd73抗体及其用途 |
CN110869393A (zh) * | 2018-03-07 | 2020-03-06 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2019106663A (ru) * | 2016-08-12 | 2020-09-14 | Мерк Патент Гмбх | Комбинированная терапия рака |
CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
WO2018237157A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
-
2019
- 2019-09-05 CN CN201910838651.0A patent/CN112442132A/zh active Pending
-
2020
- 2020-09-04 CN CN202080002411.8A patent/CN112703206B/zh active Active
- 2020-09-04 WO PCT/CN2020/113357 patent/WO2021043229A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106103488A (zh) * | 2014-02-10 | 2016-11-09 | 默克专利有限公司 | 靶向TGFβ抑制 |
CN107001474A (zh) * | 2014-11-21 | 2017-08-01 | 百时美施贵宝公司 | 抗cd73抗体及其用途 |
CN104788567A (zh) * | 2015-01-21 | 2015-07-22 | 武汉友芝友生物制药有限公司 | 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用 |
CN106467574A (zh) * | 2015-08-20 | 2017-03-01 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
CN110869393A (zh) * | 2018-03-07 | 2020-03-06 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
BRINKMANN,U.等: "The making of bispecific antibodies", 《MABS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113450877A (zh) * | 2021-06-28 | 2021-09-28 | 深圳裕泰抗原科技有限公司 | 一种基于多重免疫组化技术的生物标志物分析方法及其应用 |
CN113450877B (zh) * | 2021-06-28 | 2022-04-08 | 深圳裕泰抗原科技有限公司 | 一种基于多重免疫组化技术的生物标志物分析方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112442132A (zh) | 2021-03-05 |
WO2021043229A1 (zh) | 2021-03-11 |
CN112703206B (zh) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230025572A1 (en) | High avidity antigen recognizing constructs | |
CN109096396B (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
EP3369745B1 (en) | Anti-pd-l1 nanobody and use thereof | |
US10556954B2 (en) | Anti-PD-L1 nanobody, coding sequence and use thereof | |
CN112703206B (zh) | 靶向肿瘤的重组双功能融合蛋白及其应用 | |
UA125717C2 (uk) | Конструкція антитіла до flt3 і cd3 | |
KR20120051603A (ko) | 항카드헤린 항체 | |
US11351251B2 (en) | Anti-PD-L1-anti-TIM-3 bispecific antibodies | |
CN110835374A (zh) | 抗ccr8×ctla-4双特异性抗体及其应用 | |
EP4209503A1 (en) | Il-2 mutant and application thereof | |
CN110885376A (zh) | 抗cd47/cd20双特异性抗体及其用途 | |
TW202039578A (zh) | Cd3結合分子 | |
CN113906052A (zh) | 一种抗ceacam5的单克隆抗体及其制备方法和用途 | |
EP4269442A1 (en) | Mesothelin binding molecule and application thereof | |
TW202309083A (zh) | 抗cldn4-抗cd137雙特異性抗體 | |
CN115768797A (zh) | 抗b7-h3抗体及其制备和应用 | |
CN115109154A (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
CN110291107B (zh) | 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体 | |
US20220267436A1 (en) | Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof | |
CN115304680A (zh) | 基于Pep42构建的双特异性细胞接合器分子的制备及其应用 | |
US20220332848A1 (en) | Anti-cd47/anti-ctla-4 bispecific antibody and preparation method therefor and application thereof | |
JP2022513321A (ja) | 固形腫瘍を治療するための遺伝子操作しているγδ-T細胞及び遺伝子操作していないγδ-T細胞に関する組成物及び方法 | |
CN114773485B (zh) | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 | |
US20230365686A1 (en) | Humanized antibody specific for cd22 and chimeric antigen receptor using the same | |
US20230151113A1 (en) | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210831 Address after: 200433 No. 220, Handan Road, Shanghai, Yangpu District Applicant after: FUDAN University Applicant after: Bailisikang biomedical (Hangzhou) Co.,Ltd. Address before: 200433 No. 220, Handan Road, Shanghai, Yangpu District Applicant before: FUDAN University |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |